AIM: To evaluate the 5-lipoxygenases (Loxs) expression level in human colorectal cancer specimens in order to determine its clinicopathologic significance in human tumorigenesis. METHODS: The relative quantity of 5-Lo...AIM: To evaluate the 5-lipoxygenases (Loxs) expression level in human colorectal cancer specimens in order to determine its clinicopathologic significance in human tumorigenesis. METHODS: The relative quantity of 5-Lox mRNA in paired 91 colorectal tumor and adjacent normal mucosa samples was determined by real time quantitative PCR. Additionally, the expression of 5-Lox and cyclooxygenase (Cox)-2 proteins was also examined using immunohistochemical staining methods. RESULTS: There was a marked increase in 5-Lox mRNA levels in the tumor compared with paired normal mucosa samples (P < 0.0001). Sixty six (72.5%) tumors showed high 5-Lox mRNA levels. The positivity rate of 5-Lox and Cox-2 protein expression was 68.7% and 79.1% respectively. There was a significant association between tumoral 5-Lox mRNA level and tumor size (Rho = 0.392, P = 0.0002), depth or vessel invasion. CONCLUSION: These results suggest that 5-Lox is up-regulated in colorectal cancer and that inhibition of its expression might be valuable in the prevention and treatment of colorectal cancer.展开更多
Arachidonic acid-metabolizing enzyme 5-lipoxygenase (5-LOX) produces pro-inflammatory mediators:leukotrienes (including cysteinyl leukotrienes, CysLTs). 5-LOX and CysLTs are involved in the pathophysiological process ...Arachidonic acid-metabolizing enzyme 5-lipoxygenase (5-LOX) produces pro-inflammatory mediators:leukotrienes (including cysteinyl leukotrienes, CysLTs). 5-LOX and CysLTs are involved in the pathophysiological process after brain injury, and the actions of CysLTs are mediated via activation of their receptors, CysLT1 and CysLT2. We have recently reported the expressions of 5-LOX, CysLT1 and CysLT2 in human brains with traumatic injury and tumors, and short-term neuroprotective effects of Cys-LT1 antagonists in stroke models of rats and mice.展开更多
文摘AIM: To evaluate the 5-lipoxygenases (Loxs) expression level in human colorectal cancer specimens in order to determine its clinicopathologic significance in human tumorigenesis. METHODS: The relative quantity of 5-Lox mRNA in paired 91 colorectal tumor and adjacent normal mucosa samples was determined by real time quantitative PCR. Additionally, the expression of 5-Lox and cyclooxygenase (Cox)-2 proteins was also examined using immunohistochemical staining methods. RESULTS: There was a marked increase in 5-Lox mRNA levels in the tumor compared with paired normal mucosa samples (P < 0.0001). Sixty six (72.5%) tumors showed high 5-Lox mRNA levels. The positivity rate of 5-Lox and Cox-2 protein expression was 68.7% and 79.1% respectively. There was a significant association between tumoral 5-Lox mRNA level and tumor size (Rho = 0.392, P = 0.0002), depth or vessel invasion. CONCLUSION: These results suggest that 5-Lox is up-regulated in colorectal cancer and that inhibition of its expression might be valuable in the prevention and treatment of colorectal cancer.
文摘Arachidonic acid-metabolizing enzyme 5-lipoxygenase (5-LOX) produces pro-inflammatory mediators:leukotrienes (including cysteinyl leukotrienes, CysLTs). 5-LOX and CysLTs are involved in the pathophysiological process after brain injury, and the actions of CysLTs are mediated via activation of their receptors, CysLT1 and CysLT2. We have recently reported the expressions of 5-LOX, CysLT1 and CysLT2 in human brains with traumatic injury and tumors, and short-term neuroprotective effects of Cys-LT1 antagonists in stroke models of rats and mice.